An Overview of siRNA Delivery Strategies for Urological Cancers

被引:8
|
作者
Halib, Nadia [1 ]
Pavan, Nicola [2 ]
Trombetta, Carlo [2 ]
Dapas, Barbara [3 ]
Farra, Rossella [3 ]
Scaggiante, Bruna [3 ]
Grassi, Mario [4 ]
Grassi, Gabriele [3 ]
机构
[1] Univ Sains Islam Malaysia, Fac Dent, Dept Basic Sci & Oral Biol, Kuala Lumpur 55100, Malaysia
[2] Univ Trieste, Dept Med Surg & Hlth Sci, Urol Clin, I-34149 Trieste, Italy
[3] Trieste Univ, Cattinara Univ Hosp, Dept Life Sci, Str Fiume 447, I-34149 Trieste, Italy
[4] Trieste Univ, Dept Engn & Architecture, Via Valerio 6, I-34127 Trieste, Italy
关键词
bladder cancer; prostate cancer; renal cancer; siRNA; delivery; PROSTATE-CANCER; IN-VITRO; BLADDER-CANCER; DRUG-DELIVERY; SIOG GUIDELINES; ULTRASONIC DRUG; KINASE; NANOPARTICLES; EXPRESSION; CARCINOMA;
D O I
10.3390/pharmaceutics14040718
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers.
引用
收藏
页数:27
相关论文
共 50 条
  • [21] Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers
    Subhan, Md Abdus
    Filipczak, Nina
    Torchilin, Vladimir P.
    PHARMACEUTICALS, 2023, 16 (07)
  • [22] Highlighting function of Wnt signalling in urological cancers: Molecular interactions, therapeutic strategies, and (nano)strategies
    Hashemi, Mehrdad
    Rezaei, Mahdi
    Rezaeiaghdam, Hadi
    Jamali, Behdokht
    Koohpar, Zeinab Khazaei
    Tanha, Mahsa
    Bizhanpour, Anahita
    Asadi, Saba
    Jafari, Ali Moghadas
    Khosroshahi, Elaheh Mohandesi
    Eslami, Maedeh
    Salimimoghadam, Shokooh
    Nabavi, Noushin
    Rashidi, Mohsen
    Fattah, Eisa
    Taheriazam, Afshin
    Entezari, Maliheh
    TRANSLATIONAL ONCOLOGY, 2024, 50
  • [23] Laparoscopy for urological cancers
    Shah, J
    Vale, J
    Darzi, A
    BJU INTERNATIONAL, 2001, 88 (06) : 493 - 499
  • [24] GENETICS OF UROLOGICAL CANCERS
    MAHER, ER
    BRITISH MEDICAL BULLETIN, 1994, 50 (03) : 698 - 707
  • [25] Fucosylation in Urological Cancers
    Fujita, Kazutoshi
    Hatano, Koji
    Hashimoto, Mamoru
    Tomiyama, Eisuke
    Miyoshi, Eiji
    Nonomura, Norio
    Uemura, Hirotsugu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [26] Results in urological cancers
    不详
    BULLETIN DU CANCER, 2003, 90 : S80 - S87
  • [27] IMMUNOTHERAPY AND UROLOGICAL CANCERS
    THIOUNN, N
    MATHIOT, C
    PEYRET, C
    FLAM, T
    ZERBIB, M
    FRIDMAN, H
    DEBRE, B
    PATHOLOGIE BIOLOGIE, 1994, 42 (01): : 66 - 67
  • [28] Epigenetics of Urological Cancers
    Schulz, Wolfgang A.
    Sorensen, Karina D.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (19)
  • [29] Surgery for urological cancers
    Sengupta, Shomik
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (06) : 3007 - 3008
  • [30] Met in Urological Cancers
    Miyata, Yasuyoshi
    Asai, Akihiro
    Mitsunari, Kensuke
    Matsuo, Tomohiro
    Ohba, Kojiro
    Mochizuki, Yasushi
    Sakai, Hideki
    CANCERS, 2014, 6 (04): : 2387 - 2403